SCYNEXIS
Clinical-stage biotechnology company developing small-molecule therapies for severe rare diseases and serious fungal infections. Portfolio includes a direct AMPK activator being developed for autosomal dominant polycystic kidney disease (ADPKD) and a triterpenoid antifungal program for invasive and drug-resistant fungal infections. The company conducts preclinical research, clinical development (Phase 1/2), CMC and formulation work, and strategic partnering and licensing activities.
Industries
Nr. of Employees
medium (51-250)
SCYNEXIS
Jersey City, New Jersey, United States
Patents
Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia
US-12594266-B2
View Details
Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia
US-12594266-B2
View DetailsProducts
SCY-770 (direct AMPK activator)
Oral small-molecule direct activator of AMPK being developed as a potential disease-modifying therapy for autosomal dominant polycystic kidney disease (ADPKD); has completed multiple early clinical trials and holds Orphan Drug designation for ADPKD.
SCY-247 (second-generation triterpenoid antifungal)
Next-generation triterpenoid antifungal in development for oral and intravenous use to treat and prevent invasive and drug-resistant fungal infections; has received QIDP and Fast Track designations.
Approved licensed triterpenoid antifungal medicine (licensed to a commercial partner)
An approved triterpenoid glucan synthase inhibitor that was developed and subsequently licensed to a global pharmaceutical partner for commercialization in most major markets.
SCY-770 (direct AMPK activator)
Oral small-molecule direct activator of AMPK being developed as a potential disease-modifying therapy for autosomal dominant polycystic kidney disease (ADPKD); has completed multiple early clinical trials and holds Orphan Drug designation for ADPKD.
SCY-247 (second-generation triterpenoid antifungal)
Next-generation triterpenoid antifungal in development for oral and intravenous use to treat and prevent invasive and drug-resistant fungal infections; has received QIDP and Fast Track designations.
Approved licensed triterpenoid antifungal medicine (licensed to a commercial partner)
An approved triterpenoid glucan synthase inhibitor that was developed and subsequently licensed to a global pharmaceutical partner for commercialization in most major markets.
Services
Negotiation and execution of licensing and collaboration agreements to advance development and commercialization through regional and global partners.
Operational management of preclinical studies, early-phase clinical trials, vendor/CRO oversight, and clinical supply logistics for investigational small-molecule programs.
Negotiation and execution of licensing and collaboration agreements to advance development and commercialization through regional and global partners.
Operational management of preclinical studies, early-phase clinical trials, vendor/CRO oversight, and clinical supply logistics for investigational small-molecule programs.
Expertise Areas
- Clinical trial management
- Preclinical pharmacology and toxicology
- Antifungal drug discovery and development
- Rare disease (AMPK-targeted) therapeutics
Key Technologies
- Direct AMPK activation
- Glucan synthase inhibition
- Triterpenoid antifungal chemistry
- In vitro antifungal susceptibility testing
News & Updates
Announcement of completion of a Phase 1 study of an intravenous formulation of a triterpenoid antifungal candidate in development for treatment and prevention of invasive fungal diseases.
Publication of Phase 1 study results for a novel, highly selective oral direct AMPK activator being developed for ADPKD.
Announcement of a BARDA contract providing government funding to support development of the second-generation triterpenoid antifungal program.
Announcement that first participants were dosed in a Phase 1 single ascending dose and multiple ascending dose trial of an AMPK activator for ADPKD.
Development and subsequent licensing of a triterpenoid glucan synthase inhibitor that received FDA approval and was out-licensed to a commercial partner.
Announcement of completion of a Phase 1 study of an intravenous formulation of a triterpenoid antifungal candidate in development for treatment and prevention of invasive fungal diseases.
Publication of Phase 1 study results for a novel, highly selective oral direct AMPK activator being developed for ADPKD.
Announcement of a BARDA contract providing government funding to support development of the second-generation triterpenoid antifungal program.
Announcement that first participants were dosed in a Phase 1 single ascending dose and multiple ascending dose trial of an AMPK activator for ADPKD.
Development and subsequent licensing of a triterpenoid glucan synthase inhibitor that received FDA approval and was out-licensed to a commercial partner.